“Immunogenicity and safety of Cervarix HPV-16/18 AS04-adjuvant vaccine against HPV induced cervical cancer in women (15+ years)” (2024) UCC Student Medical Journal, 3, pp. 50–61. doi:10.33178/SMJ.2023.1.5.